PURPOSE OF REVIEW To hear from living kidney donors and recipients about what they perceive are the barriers to living donor kidney transplantation, and how patients can develop and lead innovative solutions to increase the rate and enhance the experiences of living donor kidney transplantation in Ontario. SOURCES OF INFORMATION A one-day patient-led workshop on March 10th, 2016 in Toronto, O...

High-dose chemoradiotherapy followed by marrow transplantation from an HLA-matched sibling donor is curative for patients with acute leukemia. Autologous marrow transplantation has been used with success for some patients without such a sibling. Alternatively, the option of performing a transplant from an HLA-matched unrelated donor has been made possible by the recent development of large regi...

PURPOSE Routine evaluation of kidney donors occasionally reveals an incidental renal mass with an otherwise satisfactory kidney function. The use of such a kidney with an enhancing mass for transplantation is a matter of debate owing to a possible risk of transmission of donor malignancies. We report our experience of kidney transplants from donors with renal cell carcinoma, after ex vivo resec...

Kidney transplantation, particularly from a living donor, is considered the treatment of choice for selected patients with end-stage renal disease (ESRD). A successful transplantation not only provides a better quality of life but also a survival advantage to the transplanted patient [1]. The superior results which can be achieved with kidney transplantation from living donors and the limited s...

The purpose of this study was to compare transplantation outcomes in patients with hematologic malignancies who received marrow grafts from either phenotypically matched unrelated, one-antigen-mismatched unrelated, or highly human leukocyte antigen (HLA)-disparate family donors. Between 1993 and 2000, 139 patients underwent transplantation from unrelated donors (81 matched and 58 mismatched) an...

Between April 1988 and July 1998, 510 patients with myelodysplastic syndromes (MDS) underwent unrelated donor bone marrow transplantation (BMT) facilitated by the National Marrow Donor Program. Median age was 38 years (range, <1-62 years). Several conditioning regimens and graft-versus-host disease (GVHD) prophylaxis methods were used, and T-cell depletion was used in 121 patients. Donors were ...

The demand for kidney transplantation is ever growing all over the world. Many centers are not able to accept related kidney donors due to blood group incompatibility. The waiting period for deceased donor transplantation is often very long, preventing patients from undergoing transplantation. Hence it becomes essential to increase the donor pool. ABO incompatible kidney transplantations (ABOi ...